Name | Parecoxib |
Synonyms | Valus-P SC 69124 Dynastat Parecoxib UNII-9TUW81Y3CE Parecoxib (free) Valdecoxib Impurity J Parecoxib SodiuM IMpurity W N-[4-(5-methyl-3-phenyl-oxazol-4-yl)phenyl]sulfonylpropanamide N-(4-(5-Methyl-3-phenylisoxazol-4-yl)phenylsulfonyl)propionaMide N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- N-((4-(5-Methyl-3-phenyl-2,3-dihydrooxazol-4-yl)phenyl)sulfonyl)propionaMide |
CAS | 198470-84-7 |
EINECS | 803-261-6 |
InChI | InChI=1/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) |
Molecular Formula | C19H18N2O4S |
Molar Mass | 370.42 |
Density | 1.264 |
Melting Point | 148.9-151° |
Appearance | neat |
BRN | 8640266 |
pKa | 5.08±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.58 |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vivo study | Parecoxib, a selective COX-2 inhibitor, ameliorates neurological deficits, including neuronal death and brain edema, in experimental and behavioral studies of brain injury following subarachnoid hemorrhage in rats. Parecoxib can reduce the early expression of COX2 by inhibiting the expression of cJNK (p55), reducing IL-1β, IL-6, MCP-1, IL-8, cleaved caspase-1, Caspase-9a. Parecoxib reduces NMDAR-1 and NMDAR-2a after induced subarachnoid hemorrhage. |
Risk Codes | R63 - Possible risk of harm to the unborn child R48/22 - Harmful danger of serious damage to health by prolonged exposure if swallowed. R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
WGK Germany | 3 |
RTECS | TX1478700 |
melting point 148.9-151 °c.
Valdecoxib and n. N-dimethylpyridine were dissolved in dry Tetrahydrofuran, propionic anhydride and triethylamine were added, and stirred at room temperature. After concentration, the resulting material was dissolved in acetic acid, ethanol, washed with hydrochloric acid and brine, dried, filtered, and the filtrate was concentrated to obtain parecoxib. Parecoxib and sodium hydroxide were dissolved in ethanol and concentrated to dryness. The resulting material was dissolved in ethanol, concentrated and dried in vacuo to give parecoxib sodium.
developed by Pharmacia, Inc. and approved for marketing by the European Union in March 2002. Second-generation COX-2 (cyclooxygenase-2) inhibitors. For the short-term treatment of postoperative pain.